Gilead Sciences, Inc. Close To Dominating Second Multibillion Market With Solvadi

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

It's rare enough for a biotech to succeed, and even rarer for a biotech to ultimately dominate a therapeutic area. But to do it twice? That's almost unheard of, and yet here we are with Gilead Sciences (NASDAQ: GILD ) . Building off of a $9 billion franchise in HIV, Gilead is set to become the leader in the emerging multibillion-dollar hepatitis C (HCV) market.

Help employers find you! Check out all the jobs and post your resume.

Back to news